Top

Published in:

01-01-2021 | Probiotics | Meta-analysis

The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis

Authors: Patricia M. Bock, Gabriela H. Telo, Rafaela Ramalho, Mariana Sbaraini, Gabriel Leivas, Andreza F. Martins, Beatriz D. Schaan

Published in: Diabetologia | Issue 1/2021

Abstract

Aims/hypothesis

The aim was to conduct a systematic review and meta-analysis of randomised controlled clinical trials assessing the effect of probiotic, prebiotic or synbiotic supplementation on gut microbiota and glucose control and lipid levels in individuals with diabetes.

Methods

MEDLINE, EMBASE and the Cochrane Library were searched. The eligibility criteria for the studies was involvement of participants with a diagnosis of type 1 or type 2 diabetes. Metabolic outcomes (glucose control, insulinaemia, and lipid profile) of any probiotic, prebiotic or synbiotic supplementation related to modification of gut microbiota (prebiotics, probiotics and synbiotics) were analysed. We provided a narrative synthesis and meta-analysis of the findings on metabolic outcomes from the studies. Metabolic outcomes were extracted post-intervention and expressed as mean differences (MDs) and 95% CIs between treatment and comparator groups. We pooled the results using a random-effects meta-analysis. The meta-analysis was conducted using Review Manager (RevMan) software.

Results

After the removal of duplicates and ineligible studies, 5219 studies were retained for review of titles and abstracts. The number of articles was reduced to 130 by review, for which the full-text articles were obtained and reassessed, 38 of which were included in the final meta-analysis. Overall, the use of prebiotics, probiotics or synbiotics reduced HbA_1c levels, but did not reach the threshold for significance (−2.17 mmol/mol, 95% CI −4.37, 0.03; p = 0.05, [−0.20%, 95% CI −0.40 to 0.00; p = 0.05, I² = 66%]) and had no effect on LDL-cholesterol levels (−0.05 mmol/l; 95% CI −0.14, 0.05, p = 0.35, I² = 37%). However, their consumption decreased levels of fasting blood glucose (−0.58 mmol/l; 95% CI −0.86, −0.30; p < 0.01, I² = 60%), total cholesterol (−0.14 mmol/l; 95% CI −0.26, −0.02, p = 0.02, I² = 39%), triacylglycerols (−0.11 mmol/l; 95% CI −0.20, −0.02, p = 0.01, I²= 21%) and insulinaemia (−10.51 pmol/l; 95% CI −16.68,−4.33, p < 0.01, I² = 74%), and increased HDL-cholesterol levels (0.04 mmol/l; 95% CI 0.01, 0.07, p < 0.01, I²= 24%).

Conclusions/interpretation

In individuals with diabetes mellitus, supplementation with probiotics, prebiotics or synbiotics improved metabolic variables, although the magnitude of this effect is low. Our results suggest that consumption of probiotics, prebiotics or synbiotics may be a potential adjuvant treatment for improving metabolic outcomes.

Registration

PROSPERO ID CRD42017080071.

Available only for authorised users

Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14(2):88–98. https://doi.org/10.1038/nrendo.2017.151CrossRefPubMed

Seganfredo FB, Blume CA, Moehlecke M et al (2017) Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. Obes Rev 18(8):832–851. https://doi.org/10.1111/obr.12541CrossRefPubMed

Vallianou NG, Stratigou T, Tsagarakis S (2018) Microbiome and diabetes: where are we now? Diabetes Res Clin Pract 146:111–118. https://doi.org/10.1016/j.diabres.2018.10.008CrossRefPubMed

Chakaroun RM, Massier L, Kovacs P (2020) Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders? Nutrients 12(4). https://doi.org/10.3390/nu12041082

Moludi J, Maleki V, Jafari-Vayghyan H, Vaghef-Mehrabany E, Alizadeh M (2020) Metabolic endotoxemia and cardiovascular disease: a systematic review about potential roles of prebiotics and probiotics. Clin Exp Pharmacol Physiol 47(6):927–939. https://doi.org/10.1111/1440-1681.13250CrossRefPubMed

Hawkesworth S, Moore SE, Fulford AJ et al (2013) Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes 3:e83. https://doi.org/10.1038/nutd.2013.24CrossRefPubMedPubMedCentral

Hill C, Guarner F, Reid G et al (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11(8):506–514. https://doi.org/10.1038/nrgastro.2014.66CrossRefPubMed

Gibson GR, Hutkins R, Sanders ME et al (2017) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75CrossRefPubMed

Ebrahimzadeh Leylabadlo H, Sanaie S, Sadeghpour Heravi F, Ahmadian Z, Ghotaslou R (2020) From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol 81:104268. https://doi.org/10.1016/j.meegid.2020.104268CrossRefPubMed

10.

Everard A, Lazarevic V, Derrien M et al (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60(11):2775–2786. https://doi.org/10.2337/db11-0227CrossRefPubMedPubMedCentral

11.

Yadav H, Jain S, Sinha PR (2007) Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 23(1):62–68. https://doi.org/10.1016/j.nut.2006.09.002CrossRefPubMed

12.

Bejar W, Hamden K, Ben Salah R, Chouayekh H (2013) Lactobacillus plantarum TN627 significantly reduces complications of alloxan-induced diabetes in rats. Anaerobe 24:4–11. https://doi.org/10.1016/j.anaerobe.2013.08.006CrossRefPubMed

13.

Andersson U, Bränning C, Ahrné S et al (2010) Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benefic Microbes 1(2):189–196. https://doi.org/10.3920/BM2009.0036CrossRef

14.

Yun SI, Park HO, Kang JH (2009) Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 107(5):1681–1686. https://doi.org/10.1111/j.1365-2672.2009.04350.xCrossRefPubMed

15.

Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC, Wu CS (2013) Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab (Lond) 10(1):35. https://doi.org/10.1186/1743-7075-10-35CrossRef

16.

Honda K, Moto M, Uchida N, He F, Hashizume N (2012) Anti-diabetic effects of lactic acid bacteria in normal and type 2 diabetic mice. J Clin Biochem Nutr 51(2):96–101. https://doi.org/10.3164/jcbn.11-07CrossRefPubMedPubMedCentral

17.

Kim SH, Huh CS, Choi ID et al (2014) The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo. J Appl Microbiol 117(3):834–845. https://doi.org/10.1111/jam.12573CrossRefPubMed

18.

Chen P, Zhang Q, Dang H et al (2014) Antidiabetic effect of Lactobacillus casei CCFM0412 on mice with type 2 diabetes induced by a high-fat diet and streptozotocin. Nutrition 30(9):1061–1068. https://doi.org/10.1016/j.nut.2014.03.022CrossRefPubMed

19.

Valladares R, Sankar D, Li N et al (2010) Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One 5(5):e10507. https://doi.org/10.1371/journal.pone.0010507CrossRefPubMedPubMedCentral

20.

Asemi Z, Alizadeh SA, Ahmad K, Goli M, Esmaillzadeh A (2016) Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 35(4):819–825. https://doi.org/10.1016/j.clnu.2015.07.009CrossRefPubMed

21.

Bayat A, Azizi-Soleiman F, Heidari-Beni M et al (2016) Effect of Cucurbita ficifolia and probiotic yogurt consumption on blood glucose, lipid profile, and inflammatory marker in type 2 diabetes. Int J Prev Med 7:30. https://doi.org/10.4103/2008-7802.175455CrossRefPubMedPubMedCentral

22.

Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A et al (2011) Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 94(7):3288–3294. https://doi.org/10.3168/jds.2010-4128CrossRefPubMed

23.

Hove KD, Brøns C, Færch K, Lund SS, Rossing P, Vaag A (2015) Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. Eur J Endocrinol 172(1):11–20. https://doi.org/10.1530/EJE-14-0554CrossRefPubMed

24.

Mazloom Z, Yousefinejad A, Dabbaghmanesh MH (2013) Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci 38(1):38–43PubMedPubMedCentral

25.

Nikbakht E, Khalesi S, Singh I, Williams LT, West NP, Colson N (2018) Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials. Eur J Nutr 57(1):95–106. https://doi.org/10.1007/s00394-016-1300-3CrossRefPubMed

26.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. https://doi.org/10.1016/j.jclinepi.2009.06.005CrossRefPubMed

27.

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898CrossRefPubMed

28.

Cochrane handbook for systematic reviews of interventions, version 6.0 (updated July 2019). Higgins JPT, Thomas J, Chandler J et al (eds). Cochrane, 2019. Available from www.training.Cochrane.org/handbook. Accessed 10 March 2020

29.

Zare Javid A, Aminzadeh M, Haghighi-Zadeh MH, Jamalvandi M (2020) The effects of synbiotic supplementation on glycemic status, lipid profile, and biomarkers of oxidative stress in type 1 diabetic patients. A placebo-controlled, double-blind, randomized clinical trial. Diabetes Metab Syndr Obes 13:607–617. https://doi.org/10.2147/DMSO.S238867CrossRefPubMedPubMedCentral

30.

Raygan F, Ostadmohammadi V, Bahmani F, Asemi Z (2018) The effects of vitamin D and probiotic co-supplementation on mental health parameters and metabolic status in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Prog Neuro-Psychopharmacol Biol Psychiatry 84(Pt A):50–55. https://doi.org/10.1016/j.pnpbp.2018.02.007CrossRef

31.

Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V (2012) Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 28(5):539–543. https://doi.org/10.1016/j.nut.2011.08.013CrossRefPubMed

32.

Mohamadshahi M, Veissi M, Haidari F, Javid AZ, Mohammadi F, Shirbeigi E (2014) Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: a randomized controlled clinical trial. J Res Med Sci 19(6):531–536PubMedPubMedCentral

33.

Ostadrahimi A, Taghizadeh A, Mobasseri M et al (2015) Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health 44(2):228–237PubMedPubMedCentral

34.

Sato J, Kanazawa A, Azuma K et al (2017) Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep 7(1):12115. https://doi.org/10.1038/s41598-017-12535-9CrossRefPubMedPubMedCentral

35.

Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS (2017) Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr 36(1):85–92. https://doi.org/10.1016/j.clnu.2015.11.011CrossRefPubMed

36.

Feizollahzadeh S, Ghiasvand R, Rezaei A, Khanahmad H, Sadeghi A, Hariri M (2017) Effect of probiotic soy milk on serum levels of adiponectin, inflammatory mediators, lipid profile, and fasting blood glucose among patients with type II diabetes mellitus. Probiotics Antimicrob Proteins 9(1):41–47. https://doi.org/10.1007/s12602-016-9233-yCrossRefPubMed

37.

Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K (2012) Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 11:29. https://doi.org/10.1186/1476-511X-11-29CrossRefPubMedPubMedCentral

38.

Gonai M, Shigehisa A, Kigawa I et al (2017) Galacto-oligosaccharides ameliorate dysbiotic Bifidobacteriaceae decline in Japanese patients with type 2 diabetes. Benefic Microbes 8(5):705–716. https://doi.org/10.3920/BM2016.0230CrossRef

39.

Xu J, Lian F, Zhao L et al (2015) Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J 9(3):552–562. https://doi.org/10.1038/ismej.2014.177CrossRefPubMed

40.

Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A (2013) Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 63(1–2):1–9. https://doi.org/10.1159/000349922CrossRefPubMed

41.

Ebrahimi ZS, Nasli-Esfahani E, Nadjarzade A, Mozaffari-Khosravi H (2017) Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. J Diabetes Metab Disord 16:23. https://doi.org/10.1186/s40200-017-0304-8CrossRefPubMedPubMedCentral

42.

Tajabadi-Ebrahimi M, Sharifi N, Farrokhian A et al (2017) A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease. Exp Clin Endocrinol Diabetes 125(1):21–27. https://doi.org/10.1055/s-0042-105441CrossRefPubMed

43.

Khalili L, Alipour B, Asghari Jafar-Abadi M et al (2019) The effects of Lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-A levels in patients with type 2 diabetes mellitus: a randomized controlled trial. Iran Biomed J 23(1):68–77CrossRefPubMedPubMedCentral

44.

Mafi A, Namazi G, Soleimani A, Bahmani F, Aghadavod E, Asemi Z (2018) Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Food Funct 9(9):4763–4770. https://doi.org/10.1039/c8fo00888dCrossRefPubMed

45.

Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A (2019) The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial. Diabetes Metab Syndr 13(1):175–182. https://doi.org/10.1016/j.dsx.2018.08.008CrossRefPubMed

46.

Sanborn VE, Azcarate-Peril MA, Gunstad J (2020) Lactobacillus rhamnosus GG and HbA_1c in middle age and older adults without type 2 diabetes mellitus: a preliminary randomized study. Diabetes Metab Syndr 14(5):907–909. https://doi.org/10.1016/j.dsx.2020.05.034CrossRefPubMed

47.

Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S (2019) Efficacy of UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes mellitus: a double blind, randomized, placebo controlled study. PLoS One 14(11):e0225168. https://doi.org/10.1371/journal.pone.0225168CrossRefPubMedPubMedCentral

48.

Mirmiranpour H, Huseini HF, Derakhshanian H, Khodaii Z, Tavakoli-Far B (2019) Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic control and antioxidant status in people with type 2 diabetes; a randomized, double-blind, placebo-controlled study. J Diabetes Metab Disord 19(1):53–60. https://doi.org/10.1007/s40200-019-00474-3CrossRefPubMedPubMedCentral

49.

Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY (2017) Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr 56(4):1535–1550. https://doi.org/10.1007/s00394-016-1199-8CrossRefPubMed

50.

Pedersen C, Gallagher E, Horton F et al (2016) Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake. Br J Nutr 116(11):1869–1877. https://doi.org/10.1017/S0007114516004086CrossRefPubMed

51.

Sabico S, Al-Mashharawi A, Al-Daghri NM et al (2017) Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial. J Transl Med 15(1):249. https://doi.org/10.1186/s12967-017-1354-xCrossRefPubMedPubMedCentral

52.

Sabico S, Al-Mashharawi A, Al-Daghri NM et al (2019) Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial. Clin Nutr 38(4):1561–1569. https://doi.org/10.1016/j.clnu.2018.08.009CrossRefPubMed

53.

Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, Kyriienko D, Komissarenko I (2018) Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial. Diabetes Metab Syndr 12(5):617–624. https://doi.org/10.1016/j.dsx.2018.04.015CrossRefPubMed

54.

Horvath A, Leber B, Feldbacher N et al (2019) Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Eur J Nutr. https://doi.org/10.1007/s00394-019-02135-w

55.

Mobini R, Tremaroli V, Ståhlman M et al (2017) Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 19(4):579–589. https://doi.org/10.1111/dom.12861CrossRefPubMed

56.

Roshanravan N, Mahdavi R, Alizadeh E et al (2017) Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: a randomized double-blind, placebo-controlled trial. Horm Metab Res 49(11):886–891. https://doi.org/10.1055/s-0043-119089CrossRefPubMed

57.

Sheth M, Chand V, Thakuria (2015) Inflated levels of SCFA, Bifidobacteria and Lactobacillus improves the status of pre hypertension and type 2 diabetes mellitus in subjects residing in north east India—a randomized control trial with synbiotic supplementation. Int J Curr Pharm Res 7(3):33–36

58.

Gargari BP, Dehghan P, Aliasgharzadeh A, Asghari Jafar-Abadi M (2013) Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 37(2):140–148. https://doi.org/10.4093/dmj.2013.37.2.140CrossRef

59.

Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A (2014) Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33(2):198–203. https://doi.org/10.1016/j.clnu.2013.05.015CrossRefPubMed

60.

Shakeri H, Hadaegh H, Abedi F et al (2014) Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids 49(7):695–701. https://doi.org/10.1007/s11745-014-3901-zCrossRefPubMed

61.

Tajadadi-Ebrahimi M, Bahmani F, Shakeri H et al (2014) Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial. Ann Nutr Metab 65(1):34–41. https://doi.org/10.1159/000365153CrossRefPubMed

62.

Zmora N, Zilberman-Schapira G, Suez J et al (2018) Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174(6):1388–1405.e21. https://doi.org/10.1016/j.cell.2018.08.041CrossRefPubMed

63.

Gargari G, Taverniti V, Koirala R, Gardana C, Guglielmetti S (2020) Impact of a multistrain probiotic formulation with high bifidobacterial content on the fecal bacterial community and short-chain fatty acid levels of healthy adults. Microorganisms 8(4):492. https://doi.org/10.3390/microorganisms8040492CrossRefPubMedCentral

64.

Panwar H, Calderwood D, Grant IR, Grover S, Green BD (2014) Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. Eur J Nutr 53(7):1465–1474. https://doi.org/10.1007/s00394-013-0649-9CrossRefPubMed

65.

de Goffau MC, Luopajärvi K, Knip M et al (2013) Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 62(4):1238–1244. https://doi.org/10.2337/db12-0526CrossRefPubMedPubMedCentral

66.

Sharma S, Tripathi P (2019) Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem 63:101–108. https://doi.org/10.1016/j.jnutbio.2018.10.003CrossRefPubMed

67.

Cox AJ, Zhang P, Bowden DW et al (2017) Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab 43(2):163–166. https://doi.org/10.1016/j.diabet.2016.09.004CrossRefPubMed

68.

Sato J, Kanazawa A, Ikeda F et al (2014) Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37(8):2343–2350. https://doi.org/10.2337/dc13-2817CrossRefPubMed

69.

Li X, Watanabe K, Kimura I (2017) Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases. Front Immunol 8:1882. https://doi.org/10.3389/fimmu.2017.01882CrossRefPubMedPubMedCentral

70.

Ferrari F, Bock PM, Motta MT, Helal L (2019) Biochemical and molecular mechanisms of glucose uptake stimulated by physical exercise in insulin resistance state: role of inflammation. Arq Bras Cardiol 113(6):1139–1148. https://doi.org/10.5935/abc.20190224CrossRefPubMedPubMedCentral

71.

de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V et al (2017) Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40(1):54–62. https://doi.org/10.2337/dc16-1324CrossRefPubMed

72.

DeFronzo RA, Stonehouse AH, Han J, Wintle ME (2010) Relationship of baseline HbA_1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27(3):309–317. https://doi.org/10.1111/j.1464-5491.2010.02941.xCrossRefPubMed

73.

Keng MJ, Tsiachristas A, Leal J, Gray A, Mihaylova B (2019) Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. Diabetes Obes Metab 21(11):2405–2412. https://doi.org/10.1111/dom.13821CrossRefPubMed

74.

Companys J, Pla-Pagà L, Calderón-Pérez L et al (2020) Fermented dairy products, probiotic supplementation, and cardiometabolic diseases: A systematic review and meta-analysis. Adv Nutr 11(4):834–863. https://doi.org/10.1093/advances/nmaa030CrossRefPubMedPubMedCentral

75.

Ye X, Kong W, Zafar MI, Chen LL (2019) Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol 18(1):48. https://doi.org/10.1186/s12933-019-0851-zCrossRefPubMedPubMedCentral

76.

Fiorentino TV, Succurro E, Marini MA et al (2020) HDL cholesterol is an independent predictor of β cell function decline and incident type 2 diabetes: a longitudinal study. Diabetes Metab Res Rev. https://doi.org/10.1002/dmrr.3289

Title: The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis
Authors: Patricia M. Bock
Gabriela H. Telo
Rafaela Ramalho
Mariana Sbaraini
Gabriel Leivas
Andreza F. Martins
Beatriz D. Schaan
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Probiotics
Respiratory Microbiota
Diabetes
Published in: Diabetologia / Issue 1/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-020-05295-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Hypothalamic MC4R regulates glucose homeostasis through adrenaline-mediated control of glucose reabsorption via renal GLUT2 in mice

Up front

Temporal trends in rates of infection-related hospitalisations in Hong Kong people with and without diabetes, 2001–2016: a retrospective study

Mortality in first- and second-generation immigrants to Sweden diagnosed with type 2 diabetes: a 10 year nationwide cohort study

Adipocyte-specific deletion of Tcf7l2 induces dysregulated lipid metabolism and impairs glucose tolerance in mice

Subcellular localisation and composition of intramuscular triacylglycerol influence insulin sensitivity in humans

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page